Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer

Despite advances in immunotherapy for the treatment of cancers, not all patients can benefit from programmed cell death ligand 1 (PD-L1) immune checkpoint blockade therapy. Anti-PD-L1 therapeutic effects reportedly correlate with the PD-L1 expression level; hence, accurate detection of PD-L1 express...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yinfei, Zhu, Shiyu, Fu, Jiayu, Lin, Jianguo, Sun, Yan, Lv, Gaochao, Xie, Minhao, Xu, Tao, Qiu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805943/
https://www.ncbi.nlm.nih.gov/pubmed/36605578
http://dx.doi.org/10.1016/j.jpha.2022.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805943/
https://www.ncbi.nlm.nih.gov/pubmed/36605578
http://dx.doi.org/10.1016/j.jpha.2022.09.001

Ejemplares similares